CHF 36.75
(0.68%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -2.63 Billion CHF | 0.0% |
2022 | - CHF | 0.0% |
2021 | - CHF | 100.0% |
2020 | -3.95 Billion CHF | 0.0% |
2019 | - CHF | 100.0% |
2018 | -3.06 Billion CHF | 0.0% |
2017 | - CHF | 100.0% |
2016 | -3.21 Billion CHF | 21.99% |
2015 | -4.12 Billion CHF | 0.0% |
2014 | - CHF | 0.0% |
2013 | - CHF | 0.0% |
2012 | - CHF | 0.0% |
2011 | - CHF | 0.0% |
2010 | - CHF | 0.0% |
2009 | - CHF | 0.0% |
2008 | - CHF | 0.0% |
2007 | - CHF | 0.0% |
2006 | - CHF | 0.0% |
2005 | - CHF | 0.0% |
2004 | - CHF | 0.0% |
2003 | - CHF | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | - CHF | 100.0% |
2024 Q3 | - CHF | 0.0% |
2024 Q1 | -2.82 Billion CHF | -7.24% |
2023 Q3 | - CHF | 100.0% |
2023 Q4 | -2.63 Billion CHF | 0.0% |
2023 FY | -2.63 Billion CHF | 0.0% |
2023 Q1 | - CHF | 0.0% |
2023 Q2 | -2.57 Billion CHF | 0.0% |
2022 Q3 | - CHF | 0.0% |
2022 Q1 | - CHF | 0.0% |
2022 FY | - CHF | 0.0% |
2022 Q2 | - CHF | 0.0% |
2022 Q4 | - CHF | 0.0% |
2021 Q3 | - CHF | 0.0% |
2021 FY | - CHF | 100.0% |
2021 Q1 | - CHF | 0.0% |
2021 Q2 | - CHF | 0.0% |
2021 Q4 | - CHF | 0.0% |
2020 FY | -3.95 Billion CHF | 0.0% |
2020 Q3 | - CHF | 0.0% |
2020 Q2 | - CHF | 0.0% |
2020 Q1 | - CHF | 0.0% |
2020 Q4 | - CHF | 0.0% |
2019 Q4 | - CHF | 0.0% |
2019 FY | - CHF | 100.0% |
2019 Q2 | - CHF | 0.0% |
2019 Q1 | - CHF | 0.0% |
2018 Q2 | - CHF | 0.0% |
2018 Q4 | - CHF | 0.0% |
2018 FY | -3.06 Billion CHF | 0.0% |
2018 Q1 | - CHF | 0.0% |
2018 Q3 | - CHF | 0.0% |
2017 Q3 | - CHF | 100.0% |
2017 FY | - CHF | 100.0% |
2017 Q1 | -3.52 Billion CHF | -9.62% |
2017 Q2 | -3.33 Billion CHF | 5.37% |
2017 Q4 | - CHF | 0.0% |
2016 Q3 | - CHF | 100.0% |
2016 Q2 | -2.96 Billion CHF | -0.97% |
2016 FY | -3.21 Billion CHF | 21.99% |
2016 Q4 | -3.21 Billion CHF | 0.0% |
2016 Q1 | -2.93 Billion CHF | 28.78% |
2015 Q2 | -3.93 Billion CHF | -5.35% |
2015 Q3 | - CHF | 100.0% |
2015 Q4 | -4.12 Billion CHF | 0.0% |
2015 Q1 | -3.73 Billion CHF | 0.0% |
2015 FY | -4.12 Billion CHF | 0.0% |
2014 Q4 | - CHF | 100.0% |
2014 Q3 | -2.9 Billion CHF | -18.77% |
2014 FY | - CHF | 0.0% |
2014 Q1 | -2.26 Billion CHF | 0.0% |
2014 Q2 | -2.44 Billion CHF | -7.85% |
2013 Q4 | - CHF | 100.0% |
2013 Q1 | -1.64 Billion CHF | 0.0% |
2013 Q2 | -1.76 Billion CHF | -6.85% |
2013 Q3 | -2.16 Billion CHF | -22.77% |
2013 FY | - CHF | 0.0% |
2012 FY | - CHF | 0.0% |
2012 Q4 | - CHF | 0.0% |
2012 Q3 | - CHF | 0.0% |
2012 Q2 | - CHF | 0.0% |
2012 Q1 | - CHF | 0.0% |
2011 Q3 | - CHF | 0.0% |
2011 Q4 | - CHF | 0.0% |
2011 Q1 | - CHF | 0.0% |
2011 FY | - CHF | 0.0% |
2011 Q2 | - CHF | 0.0% |
2010 Q1 | - CHF | 0.0% |
2010 Q2 | - CHF | 0.0% |
2010 Q3 | - CHF | 0.0% |
2010 Q4 | - CHF | 0.0% |
2010 FY | - CHF | 0.0% |
2009 FY | - CHF | 0.0% |
2009 Q4 | - CHF | 0.0% |
2008 FY | - CHF | 0.0% |
2007 FY | - CHF | 0.0% |
2006 FY | - CHF | 0.0% |
2005 FY | - CHF | 0.0% |
2004 FY | - CHF | 0.0% |
2003 FY | - CHF | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Addex Therapeutics Ltd | - CHF | Infinity% |
Basilea Pharmaceutica AG | 26.41 Million CHF | 10083.54% |
Evolva Holding SA | - CHF | Infinity% |
Idorsia Ltd | 59.14 Million CHF | 4557.872% |
Kuros Biosciences AG | 4.85 Million CHF | 54396.808% |
Molecular Partners AG | - CHF | Infinity% |
Relief Therapeutics Holding AG | 557 Thousand CHF | 473466.786% |
Santhera Pharmaceuticals Holding AG | 1.81 Million CHF | 145690.999% |